Security key
720795202
PIERIS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (PIRS)
CUSIP: 720795202
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 362,206
- Total 13F value
- $3,571,986
- Share change
- +362,206
- SEC-reported price per share
- $9.82
- Number of holders
- 18
- Value change
- +$3,571,986
- Number of buys
- 18
- Shares outstanding
- 1,318,495
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
18
Top holders
10
PIRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
PALVELLA THERAPEUTICS, INC. SEC filings
PALVELLA THERAPEUTICS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 720795202
Recent filing periods:
Ownership snapshot
Top reported holders of PIRS - PIERIS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BVF INC/IL
Disclosed value leader
BVF INC/IL
Comparable rows
0/15
Latest evidence
31 Mar 2024
13F
Highest disclosed value: $3,775,727
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
BVF INC/IL has the largest disclosed position value at $3.78M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BVF INC/IL's linked filing trail.
Disclosed position value
Top 5
BVF INC/IL
$3.78M
Lynx1 Capital Management LP
$1.61M
GOLDMAN SACHS GROUP INC
$331.9K
RENAISSANCE TECHNOLOGIES LLC
$262K
BlackRock Finance, Inc.
$190.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BVF INC/IL |
13F
Company
|
—
denominator unverified
|
$3,775,727
20,609,863 shares
|
— | 31 Mar 2024 |
| Lynx1 Capital Management LP |
13F
Company
|
—
denominator unverified
|
$1,608,342
8,779,162 shares
|
— | 31 Mar 2024 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
—
denominator unverified
|
$331,873
22,638 shares
|
— | 31 Mar 2024 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$262,000
1,429,588 shares
|
— | 31 Mar 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$190,096
1,037,639 shares
|
— | 31 Mar 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$177,197
967,235 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
18
Shares
362,206
Rows available
18
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q3 2025 Across Filers
Q3 2025 holders
0
Q2 2024 holders
18
Holder diff
18
| Investor | Q3 2025 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q3 2025 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend